Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2551]

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer

ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung...

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

ASCO 2019: Patient groups untested in cancer immunotherapy trials found to also benefit

Steroids can reduce lung cancer risk in COPD patients

Steroids can reduce lung cancer risk in COPD patients

Proton therapy for cancer lowers risk of side effects

Proton therapy for cancer lowers risk of side effects

Summer School in Translational Cancer Research, Algarve, Portugal, October 7-11, 2019

Summer School in Translational Cancer Research, Algarve, Portugal, October 7-11, 2019

Rare pulmonary side effects of brigatinib often resolve without treatment discontinuation

Rare pulmonary side effects of brigatinib often resolve without treatment discontinuation

Scientists discover potential breakthrough in the understanding of tumour dormancy

Scientists discover potential breakthrough in the understanding of tumour dormancy

More from ecancer